Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab Adjuvant Therapy in MRD-Positive Esophageal Squamous Cell Carcinoma
NCT06914011Phase 3Not yet recruiting
- Sponsor
- Asan Medical Center
- Start
- Dec 2026
- Primary completion
- Jun 2031
- Modality
- Monoclonal Antibodies
01
Overview
Phase 3, randomised, open-label trial of tislelizumab in Esophageal Squamous Cell Carcinoma (ESCC) (2 arms), sponsored by Asan Medical Center. Primary endpoint: Recurrence-free survival at 5 years. Planned start Dec 2026; status: not yet recruiting.
02
Drugs
tislelizumab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT06914011.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06914011.